Tags

Type your tag names separated by a space and hit enter

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization.
Nature. 2021 08; 596(7871):276-280.Nat

Abstract

The SARS-CoV-2 B.1.617 lineage was identified in October 2020 in India1-5. Since then, it has become dominant in some regions of India and in the UK, and has spread to many other countries6. The lineage includes three main subtypes (B1.617.1, B.1.617.2 and B.1.617.3), which contain diverse mutations in the N-terminal domain (NTD) and the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein that may increase the immune evasion potential of these variants. B.1.617.2-also termed the Delta variant-is believed to spread faster than other variants. Here we isolated an infectious strain of the Delta variant from an individual with COVID-19 who had returned to France from India. We examined the sensitivity of this strain to monoclonal antibodies and to antibodies present in sera from individuals who had recovered from COVID-19 (hereafter referred to as convalescent individuals) or who had received a COVID-19 vaccine, and then compared this strain with other strains of SARS-CoV-2. The Delta variant was resistant to neutralization by some anti-NTD and anti-RBD monoclonal antibodies, including bamlanivimab, and these antibodies showed impaired binding to the spike protein. Sera collected from convalescent individuals up to 12 months after the onset of symptoms were fourfold less potent against the Delta variant relative to the Alpha variant (B.1.1.7). Sera from individuals who had received one dose of the Pfizer or the AstraZeneca vaccine had a barely discernible inhibitory effect on the Delta variant. Administration of two doses of the vaccine generated a neutralizing response in 95% of individuals, with titres three- to fivefold lower against the Delta variant than against the Alpha variant. Thus, the spread of the Delta variant is associated with an escape from antibodies that target non-RBD and RBD epitopes of the spike protein.

Authors+Show Affiliations

Virus and Immunity Unit, Department of Virology, Institut Pasteur, CNRS UMR 3569, Paris, France. Vaccine Research Institute, Creteil, France.INSERM, Functional Genomics of Solid Tumors (FunGeST), Centre de Recherche des Cordeliers, Université de Paris and Sorbonne Université, Paris, France. Laboratoire de Virologie, Service de Microbiologie, Hôpital Européen Georges Pompidou, Assistance Publique des Hôpitaux de Paris, Paris, France.G5 Evolutionary Genomics of RNA Viruses, Department of Virology, Institut Pasteur, Paris, France.Virus and Immunity Unit, Department of Virology, Institut Pasteur, CNRS UMR 3569, Paris, France.Virus and Immunity Unit, Department of Virology, Institut Pasteur, CNRS UMR 3569, Paris, France.Virus and Immunity Unit, Department of Virology, Institut Pasteur, CNRS UMR 3569, Paris, France. Université de Paris, Sorbonne Paris Cité, Paris, France.Laboratory of Humoral Immunology, Department of Immunology, Institut Pasteur, INSERM U1222, Paris, France.Virus and Immunity Unit, Department of Virology, Institut Pasteur, CNRS UMR 3569, Paris, France.Laboratoire de Virologie, Service de Microbiologie, Hôpital Européen Georges Pompidou, Assistance Publique des Hôpitaux de Paris, Paris, France.Laboratoire de Virologie, Service de Microbiologie, Hôpital Européen Georges Pompidou, Assistance Publique des Hôpitaux de Paris, Paris, France.G5 Evolutionary Genomics of RNA Viruses, Department of Virology, Institut Pasteur, Paris, France.CHU de Strasbourg, Laboratoire de Virologie, Strasbourg, France. Université de Strasbourg, INSERM, IRM UMR_S 1109, Strasbourg, France.CHU de Strasbourg, Laboratoire de Virologie, Strasbourg, France. Université de Strasbourg, INSERM, IRM UMR_S 1109, Strasbourg, France.CHU de Strasbourg, Laboratoire de Virologie, Strasbourg, France. Université de Strasbourg, INSERM, IRM UMR_S 1109, Strasbourg, France.Service de Gériatrie, Hôpital Européen Georges Pompidou, Assistance Publique des Hôpitaux de Paris, Paris, France.Unité d'Hygiène Hospitalière, Service de Microbiologie, Hôpital Européen Georges Pompidou, Assistance Publique des Hôpitaux de Paris, Paris, France.Laboratoire de Virologie, Service de Microbiologie, Hôpital Européen Georges Pompidou, Assistance Publique des Hôpitaux de Paris, Paris, France.Laboratoire de Virologie, Service de Microbiologie, Hôpital Européen Georges Pompidou, Assistance Publique des Hôpitaux de Paris, Paris, France.CHR d'Orléans, Service de Maladies Infectieuses, Orléans, France.CHR d'Orléans, Service de Maladies Infectieuses, Orléans, France.INSERM, Functional Genomics of Solid Tumors (FunGeST), Centre de Recherche des Cordeliers, Université de Paris and Sorbonne Université, Paris, France.CHR d'Orléans, Service de Maladies Infectieuses, Orléans, France.CHU de Strasbourg, Laboratoire de Virologie, Strasbourg, France. Université de Strasbourg, INSERM, IRM UMR_S 1109, Strasbourg, France.CHR d'Orléans, Service de Maladies Infectieuses, Orléans, France.Laboratory of Humoral Immunology, Department of Immunology, Institut Pasteur, INSERM U1222, Paris, France.Virus and Immunity Unit, Department of Virology, Institut Pasteur, CNRS UMR 3569, Paris, France. timothee.bruel@pasteur.fr. Vaccine Research Institute, Creteil, France. timothee.bruel@pasteur.fr.G5 Evolutionary Genomics of RNA Viruses, Department of Virology, Institut Pasteur, Paris, France.Structural Virology Unit, Department of Virology, Institut Pasteur, CNRS UMR 3569, Paris, France.Virus and Immunity Unit, Department of Virology, Institut Pasteur, CNRS UMR 3569, Paris, France. olivier.schwartz@pasteur.fr. Vaccine Research Institute, Creteil, France. olivier.schwartz@pasteur.fr.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

34237773

Citation

Planas, Delphine, et al. "Reduced Sensitivity of SARS-CoV-2 Variant Delta to Antibody Neutralization." Nature, vol. 596, no. 7871, 2021, pp. 276-280.
Planas D, Veyer D, Baidaliuk A, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature. 2021;596(7871):276-280.
Planas, D., Veyer, D., Baidaliuk, A., Staropoli, I., Guivel-Benhassine, F., Rajah, M. M., Planchais, C., Porrot, F., Robillard, N., Puech, J., Prot, M., Gallais, F., Gantner, P., Velay, A., Le Guen, J., Kassis-Chikhani, N., Edriss, D., Belec, L., Seve, A., ... Schwartz, O. (2021). Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature, 596(7871), 276-280. https://doi.org/10.1038/s41586-021-03777-9
Planas D, et al. Reduced Sensitivity of SARS-CoV-2 Variant Delta to Antibody Neutralization. Nature. 2021;596(7871):276-280. PubMed PMID: 34237773.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. AU - Planas,Delphine, AU - Veyer,David, AU - Baidaliuk,Artem, AU - Staropoli,Isabelle, AU - Guivel-Benhassine,Florence, AU - Rajah,Maaran Michael, AU - Planchais,Cyril, AU - Porrot,Françoise, AU - Robillard,Nicolas, AU - Puech,Julien, AU - Prot,Matthieu, AU - Gallais,Floriane, AU - Gantner,Pierre, AU - Velay,Aurélie, AU - Le Guen,Julien, AU - Kassis-Chikhani,Najiby, AU - Edriss,Dhiaeddine, AU - Belec,Laurent, AU - Seve,Aymeric, AU - Courtellemont,Laura, AU - Péré,Hélène, AU - Hocqueloux,Laurent, AU - Fafi-Kremer,Samira, AU - Prazuck,Thierry, AU - Mouquet,Hugo, AU - Bruel,Timothée, AU - Simon-Lorière,Etienne, AU - Rey,Felix A, AU - Schwartz,Olivier, Y1 - 2021/07/08/ PY - 2021/05/26/received PY - 2021/06/29/accepted PY - 2021/7/9/pubmed PY - 2021/8/20/medline PY - 2021/7/8/entrez SP - 276 EP - 280 JF - Nature JO - Nature VL - 596 IS - 7871 N2 - The SARS-CoV-2 B.1.617 lineage was identified in October 2020 in India1-5. Since then, it has become dominant in some regions of India and in the UK, and has spread to many other countries6. The lineage includes three main subtypes (B1.617.1, B.1.617.2 and B.1.617.3), which contain diverse mutations in the N-terminal domain (NTD) and the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein that may increase the immune evasion potential of these variants. B.1.617.2-also termed the Delta variant-is believed to spread faster than other variants. Here we isolated an infectious strain of the Delta variant from an individual with COVID-19 who had returned to France from India. We examined the sensitivity of this strain to monoclonal antibodies and to antibodies present in sera from individuals who had recovered from COVID-19 (hereafter referred to as convalescent individuals) or who had received a COVID-19 vaccine, and then compared this strain with other strains of SARS-CoV-2. The Delta variant was resistant to neutralization by some anti-NTD and anti-RBD monoclonal antibodies, including bamlanivimab, and these antibodies showed impaired binding to the spike protein. Sera collected from convalescent individuals up to 12 months after the onset of symptoms were fourfold less potent against the Delta variant relative to the Alpha variant (B.1.1.7). Sera from individuals who had received one dose of the Pfizer or the AstraZeneca vaccine had a barely discernible inhibitory effect on the Delta variant. Administration of two doses of the vaccine generated a neutralizing response in 95% of individuals, with titres three- to fivefold lower against the Delta variant than against the Alpha variant. Thus, the spread of the Delta variant is associated with an escape from antibodies that target non-RBD and RBD epitopes of the spike protein. SN - 1476-4687 UR - https://www.unboundmedicine.com/medline/citation/34237773/Reduced_sensitivity_of_SARS_CoV_2_variant_Delta_to_antibody_neutralization_ L2 - https://doi.org/10.1038/s41586-021-03777-9 DB - PRIME DP - Unbound Medicine ER -